Evidence map›Paper›PMID 19040616›Full record

ArticleClinical and experimental immunology2009

Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells.

L Jiang, X F Wei, D H Yi, P Xu, H Liu, Q Chang, S M Yang, Z F Li, H B Gao, G J Hao

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Revisiting the matricellular concept.Matrix biology : journal of the International Society for Matrix Biology · 2014
    Review
  8. Article
  9. Article
  10. An investigation of tenascin-C levels in rheumatic mitral stenosis and their response to percutaneous mitral balloon valvuloplasty.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2013
    Article
  11. Article
  12. Advances in tenascin-C biology.Cellular and molecular life sciences : CMLS · 2011
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

L JiangDepartment of Cardiac Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
X F Wei
D H Yi
P Xu
H Liu
Q Chang
S M Yang
Z F Li
H B Gao
G J Hao
Qingdao University · CNAir Force Medical University · CNSouthern Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenascin-C (TN-C) is a key component of extracellular matrix (ECM) and its expression process is poorly understood during rheumatic heart valvular disease (RHVD). In this study, we found that interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha and TN-C concentrations in patients with RHVD were significantly higher than in normal controls. More IFN-gamma receptors and TNF receptors were found being expressed on rheumatic aortic valves interstitial cells than on non-rheumatic ones and their expression was patients' sera dependent. Antibodies neutralizing IFN-gamma or TNF-alpha could attenuate patients' sera-induced TN-C transcription by isolated rheumatic aortic valves interstitial cells. By application with different protein kinase inhibitors, we found that combined with cyclic strain, TNF-alpha and IFN-gamma induced TN-C transcription through the RhoA/ROCK signalling pathway. At the same time, p38 mitogen-activated protein kinase was involved in TNF-alpha and IFN-gamma induced TN-C transcription. TNF-alpha also increased TN-C mRNA level by additional PKC and ERK 1/2 activation. Our finding revealed a new insight into ECM remodelling during RHVD pathogenesis and new mechanisms involved in the clinical anti-IFN-gamma and anti-TNF-alpha therapy.

Indexed as

AdultAortic ValveCells, CulturedCytokinesFemaleHeart-Assist DevicesHumansInterferon-gammaInterferon gamma ReceptorMaleMiddle AgedReceptors, InterferonReceptors, Tumor Necrosis FactorReverse Transcriptase Polymerase Chain ReactionRheumatic Heart DiseaseRNA, MessengerCytokinesInterferon-gammaInterferon gamma ReceptorReceptors, InterferonReceptors, Tumor Necrosis FactorRNA, MessengerTenascinTumor Necrosis Factor-alpha

Identifiers

PMID19040616
PMCPMC2675252
OpenAlexW2060293453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.